Results 41 to 50 of about 181,578 (308)

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]

, 2018
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P, Brentjens, Renier J, Cheung, Kenneth, Daniyan, Anthony F, Li, Xinghuo, Park, Hyebin, Purdon, Terence J, Spitzer, Matthew H, van Leeuwen, Dayenne G, Wijewarnasuriya, Dinali P, Yeku, Oladapo   +10 more
core   +1 more source

The Other Face of Chimeric Antigen Receptors [PDF]

Molecular Therapy, 2014
The concept of chimeric antigen receptor (CAR) was pioneered in 1989 by Eshhar and colleagues with the specific goal of providing an alternative means by which T lymphocytes can engage antigens expressed by target cells.1 Until recently, the focus of CAR–T cell research has been on achieving effector function in T lymphocytes that can target cancer ...
openaire   +2 more sources

Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella [PDF]

, 2017
Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we ...
Berguer, Paula Mercedes, Biedma, Marina Elizabeth, Blancá, Bruno Martin, Cayet, D., Errea, Agustina Juliana, Goldbaum, Fernando Alberto, Hiriart, Yanina, Moreno, Griselda Noemí, Rinaldi, Jimena Julieta, Rossi, Andrés Hugo, Rumbo, Martín, Sirard, J.C.   +11 more
core   +3 more sources

Drug functional remapping: a new promise for tumor immunotherapy

Frontiers in Oncology
The research and development of new anti-cancer drugs face challenges such as high costs, lengthy development cycles, and limited data on side effects.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Ting Su, Ting Su, Ting Su, Ting Su, Jiexiong Wu, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Minghan Song, Minghan Song, Minghan Song, Canfeng He, Canfeng He, Canfeng He, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Yubin Yang, Yubin Yang, Size Chen, Size Chen, Size Chen, Size Chen   +27 more
doaj   +1 more source

Natural killer cell immunotherapy in glioblastoma

Discover Oncology, 2022
Glioblastoma (GBM) is one of the most difficult cancers to treat because GBM has the high therapeutic resistance. Recently, immunotherapies for GBM have been used instead of conventional treatments.
Hamed Hosseinalizadeh, Mehryar Habibi Roudkenar, Amaneh Mohammadi Roushandeh, Yoshikazu Kuwahara, Kazuo Tomita, Tomoaki Sato   +5 more
doaj   +1 more source

Circumventing antivector immunity: potential use of nonhuman adenoviral vectors [PDF]

, 2014
Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase
Beard C.W., Benkö M., Cauthen A.N., Crawford-Miksza L., Estrella Lopez-Gordo, Gall J., Gall J.G., Gattoni A., Ginsberg H.S., Haviv Y.S., Hofmann C., Iva I. Podgorski, Kajon A.E., Kanerva A., Kass-Eisler A., Kuriyama S., Mastrangeli A., Michou A.I., Nicholas Downes, Ramon Alemany, Rogozhin V.N., Roy S., Seiradake E., Shmarov M.M., Soudais C., Tutykhina I.L., Wang D.Y., Wohlfart C., Ying B., Zakhartchouk A.N., Zeng Q.   +30 more
core   +3 more sources

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis

Cells, 2023
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising treatment option for patients suffering from B-cell- and plasma cell-derived hematologic malignancies and is being adapted for the treatment of solid cancers. However, CAR T is associated with
Bryanna Reinhardt, Patrick Lee, Joshua P. Sasine   +2 more
doaj   +1 more source

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. [PDF]

, 2014
The majority of chimeric antigen receptor (CAR) T-cell research has focused on attacking cancer cells. Here, we show that targeting the tumor-promoting, nontransformed stromal cells using CAR T cells may offer several advantages.
Albelda, Steven M., Antzis, Michael, Cotner, Cody E., Durham, Amy C., Johnson, Laura A., June, Carl H., Kapoor, Veena, Lo, Albert, Majumdar, Rajrupa S., Puré, Ellen, Scholler, John, Solomides, MD, Charalambos C., Sun, Jing, Wang, Liang-Chuan S.   +13 more
core   +2 more sources